The DOI matches its Crossref record.
Use of Ampicillin/Sulbactam Versus Imipenem/Cilastatin in the Treatment of Limb-Threatening Foot Infections in Diabetic Patients
Abstract
In a double-blind randomized trial, imipenem/cilastatin (I/C; 500 mg every 6 hours) and ampicillin/sulbactam (A/S; 3 g every 6 hours) were compared in regard to their efficacy for initial empirical and definitive parenteral treatment of limb-threatening pedal infection in diabetic patients. The major endpoints of treatment were cure (resolution of soft-tissue infection), failure (inadequate improvement, necessitating a change in antibiotic therapy), and eradication (clearance of all pathogens from the wound and any bone cultures). Patients in the two treatment groups were similar in regard to the severity of diabetes; presence of neuropathy and peripheral vascular disease; site and severity of infection; pathogen isolated; and frequency of osteomyelitis (associated with 68% of the 48 A/S-treated infections and 56% of the 48 I/C-treated infections). After 5 days of empirical treatment, improvement was noted in 94% of the A/S and 98% of the I/C recipients. At the end of definitive treatment (days' duration [mean +/- SD]: 13 +/- 6.5 [A/S], 14.8 +/- 8.6 [I/C]), outcomes were similar: cure, 81% (A/S) vs. 85% (I/C); failure, 17% (A/S) vs. 13% (I/C); and eradication, 67% (A/S) vs. 75% (I/C). Treatment failures were associated with the presence of antibiotic-resistant pathogens and possible nosocomial acquisition of infections. The number of adverse events among patients in the two treatment groups was similar: 7 in the A/S group (4 had diarrhea and 3 had rash) and 9 in the I/C group (5 had diarrhea, 2 had severe nausea, 1 had rash, and 1 had seizure). Efficacy of A/S and I/C is similar for initial empirical and definitive treatment of limb-threatening pedal infection in patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diagnosis and Treatment of Diabetic Foot Infections
Lipsky, B. A., Berendt, A. R., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., LeFrock, J. L., Lew, D. P., Mader, J. T., Norden, C., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424846 · Cited by 1,146
Self-citationDiabetic Foot Disorders: A Clinical Practice Guideline (2006 Revision)
Frykberg, R. G., Zgonis, T., Armstrong, D. G., Driver, V. R., Giurini, J. M., Kravitz, S. R., Landsman, A. S., Lavery, L. A., Moore, J. C., Schuberth, J. M., et al. (2006) · The Journal of Foot and Ankle Surgery · doi:10.1016/s1067-2516(07)60001-5 · Cited by 831
Russo, T. A., & Johnson, J. R. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(03)00049-2 · Cited by 801
Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment
Berendt, A. R., Peters, E. J. G., Bakker, K., Embil, J. M., Eneroth, M., Hinchliffe, R. J., Jeffcoate, W. J., Lipsky, B. A., Senneville, E., Teh, J., et al. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.836 · Cited by 319
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections
Stengel, D., Bauwens, K., Sehouli, J., Ekkernkamp, A., & Porzsolt, F. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00094-9 · Cited by 299
Metadata
- Authors
- Grayson, M. L., Gibbons, G. W., Habershaw, G. M., Freeman, D. V., Pomposelli, F. B., Rosenblum, B. I., Levin, E., & Karchmer, A. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-05-01
- Volume
- 18
- Issue
- 5
- Pages
- 683-693
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1964004587
- Cited by
- 191
- References
- 0
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Ampicillin/Sulbactam Versus Imipenem/Cilastatin in the Treatment of Limb-Threatening Foot Infections in Diabetic Patients. https://app.cochat.ai/papers/10.1093/clinids/18.5.683
- The paper
- Grayson, M. L., Gibbons, G. W., Habershaw, G. M., Freeman, D. V., Pomposelli, F. B., Rosenblum, B. I., Levin, E., & Karchmer, A. W. (1994). Use of Ampicillin/Sulbactam Versus Imipenem/Cilastatin in the Treatment of Limb-Threatening Foot Infections in Diabetic Patients. Clinical Infectious Diseases. https://doi.org/10.1093/clinids/18.5.683
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.